homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


Subscriber content preview

December 6, 2019

Experts split sharply over new Alzheimer’s drug

By MARILYNN MARCHIONE
AP Chief Medical Writer

SAN DIEGO — A company that claims to have the first drug to slow mental decline from Alzheimer’s disease made its case to scientists Thursday but left them sharply divided over whether there’s enough evidence of effectiveness for the medicine to warrant federal approval.

Excitement and skepticism have surrounded aducanumab since its developers stopped two studies earlier this year because it didn’t seem to be working, then did a stunning about-face in October and said new results suggest it was effective at a high dose.


 
. . .


To read this story in full login or purchase a subscription.




Email or user name:
Password:
 
Forgot password? Click here.